Related Experiment Videos

Clinical trial--derived risk model may not generalize to real-world patients with acute coronary syndrome

Andrew T Yan1, Philip Jong, Raymond T Yan

  • 1Terrence Donnelly Heart Centre, Division of Cardiology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.

American Heart Journal
|January 6, 2005
PubMed

Insights

The GRACE risk model better predicts in-hospital death in acute coronary syndromes (ACS) patients than the PURSUIT model. Validating risk models in general ACS populations is crucial for clinical practice.

Area of Science:

  • Cardiology
  • Clinical Risk Stratification

Background:

  • Accurate risk stratification is vital for managing acute coronary syndromes (ACS).
  • The generalizability of existing risk models to diverse ACS populations is often uncertain.
  • This study aimed to validate and compare two risk models in a contemporary, less selected ACS cohort.

Purpose of the Study:

  • To validate and compare the performance of the Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) and Global Registry of Acute Cardiac Events (GRACE) risk models.
  • To assess the applicability of these models in a contemporary, less selected population with ACS.
  • To determine which model offers superior risk assessment for in-hospital mortality.

Main Methods:

  • Prospective, observational study of 4627 ACS patients from the Canadian ACS Registry.
  • Evaluation of in-hospital mortality prediction using PURSUIT and GRACE risk models for non-ST-elevation ACS.
  • Assessment of model discrimination via c-statistic and calibration using the Hosmer-Lemeshow goodness-of-fit test.

Main Results:

  • In-hospital mortality was 2.4% overall and 1.5% in the non-ST-elevation ACS subgroup.
  • Both PURSUIT and GRACE models demonstrated strong prognostic discrimination (c-statistics 0.84 and 0.83, respectively).
  • The GRACE model showed good calibration, while the PURSUIT model exhibited poor calibration with risk overestimation.

Conclusions:

  • Both PURSUIT and GRACE models effectively discriminate in-hospital mortality in ACS patients.
  • The GRACE risk model offers superior calibration and risk assessment in a broader ACS population.
  • Emphasizes the need for validating risk models in general populations before clinical implementation.
Abstract

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).